Clinical Trial Update: A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety, and tolerability of 14 days of once-daily inhaled interferon beta-1a in asthma patients after onset of upper resp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Inhaled Interferon Beta-1a (interferon beta-1a)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-15